BRAF and neoplasm: As molecularly informed treatment strategies are becoming increasingly feasible as first-line options, identifying a tumor’s mutational makeup, including directly targetable alterations, will be essential in guiding patients toward optimal treatment, as demonstrated by targeting BRAF V600E, FGFR, ALK and NTRK in (among others) pediatric gliomas27–32.